메뉴 건너뛰기




Volumn 40, Issue 11, 2006, Pages 1955-1965

Doxercalciferol treatment of secondary hyperparathyroidism

Author keywords

Chronic kidney disease; Doxercalciferol; Secondary hyperparathyroidism

Indexed keywords

CALCITRIOL; CALCIUM; COLESTYRAMINE; DOXERCALCIFEROL; ENZYME INDUCING AGENT; ENZYME INHIBITOR; ERGOCALCIFEROL; ERYTHROMYCIN; KETOCONAZOLE; MINERAL OIL; PARATHYROID HORMONE; PARICALCITOL; PHENOBARBITAL; PHOSPHORUS; PLACEBO; VITAMIN D;

EID: 33751012147     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G523     Document Type: Review
Times cited : (13)

References (62)
  • 1
    • 23844449784 scopus 로고    scopus 로고
    • Vitamin D treatment in chronic kidney disease
    • Andress DL. Vitamin D treatment in chronic kidney disease. Semin Dial 2005;18:315-21.
    • (2005) Semin Dial , vol.18 , pp. 315-321
    • Andress, D.L.1
  • 2
    • 0027178439 scopus 로고
    • The spectrum of bone disease in end-stage renal failure - An evolving disorder
    • Sherrard DJ, Hercz G, Pei Y, et al. The spectrum of bone disease in end-stage renal failure-an evolving disorder. Kidney Int 1993;43:436-42.
    • (1993) Kidney Int , vol.43 , pp. 436-442
    • Sherrard, D.J.1    Hercz, G.2    Pei, Y.3
  • 3
    • 23844488455 scopus 로고    scopus 로고
    • Role of parathyroid hormone and therapy with active vitamin D sterols in renal osteodystrophy
    • Hernandez JD, Wesseling D, Salusky IB. Role of parathyroid hormone and therapy with active vitamin D sterols in renal osteodystrophy. Semin Dial 2005;18:290-5.
    • (2005) Semin Dial , vol.18 , pp. 290-295
    • Hernandez, J.D.1    Wesseling, D.2    Salusky, I.B.3
  • 4
    • 0031920748 scopus 로고    scopus 로고
    • Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study
    • Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17.
    • (1998) Am J Kidney Dis , vol.31 , pp. 607-617
    • Block, G.A.1    Hulbert-Shearon, T.E.2    Levin, N.W.3    Port, F.K.4
  • 6
    • 0037138580 scopus 로고    scopus 로고
    • Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?
    • Raggi P, Boulay A, Chasan-Taber SC, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39:695-701.
    • (2002) J Am Coll Cardiol , vol.39 , pp. 695-701
    • Raggi, P.1    Boulay, A.2    Chasan-Taber, S.C.3
  • 8
    • 83055172414 scopus 로고    scopus 로고
    • K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
    • National Kidney Foundation
    • National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(suppl):S1-203.
    • (2003) Am J Kidney Dis , vol.42 , Issue.SUPPL.
  • 10
    • 0033505903 scopus 로고    scopus 로고
    • Prevention of renal osteodystrophy in predialysis patients
    • Sanchez CP, Goodman WG, Salusky IB. Prevention of renal osteodystrophy in predialysis patients. Am J Med Sci 1999;317:398-404.
    • (1999) Am J Med Sci , vol.317 , pp. 398-404
    • Sanchez, C.P.1    Goodman, W.G.2    Salusky, I.B.3
  • 11
    • 0033843456 scopus 로고    scopus 로고
    • Management of secondary hyperparathyroidism: The gap between diagnosis and treatment
    • Corte-Diaz C, Andia-Cannata JB. Management of secondary hyperparathyroidism: the gap between diagnosis and treatment. Am J Med Sci 2000;320:107-11.
    • (2000) Am J Med Sci , vol.320 , pp. 107-111
    • Corte-Diaz, C.1    Andia-Cannata, J.B.2
  • 12
    • 0141526958 scopus 로고    scopus 로고
    • Update on renal osteodystrophy: Pathogenesis and clinical management
    • Sakhaee K, Gonzalez GB. Update on renal osteodystrophy: pathogenesis and clinical management. Am J Med Sci 1999:317:251-60.
    • (1999) Am J Med Sci , vol.317 , pp. 251-260
    • Sakhaee, K.1    Gonzalez, G.B.2
  • 13
    • 0033842408 scopus 로고    scopus 로고
    • Current medical management of secondary hyperparathyroidism
    • Yudd M, Llach F. Current medical management of secondary hyperparathyroidism. Am J Med Sci 2000;320:100-6.
    • (2000) Am J Med Sci , vol.320 , pp. 100-106
    • Yudd, M.1    Llach, F.2
  • 14
    • 0033839073 scopus 로고    scopus 로고
    • Adynamic bone and chronic renal failure: An overview
    • Cannata-Andia JB. Adynamic bone and chronic renal failure: an overview. Am J Med Sci 2000;320:81-4.
    • (2000) Am J Med Sci , vol.320 , pp. 81-84
    • Cannata-Andia, J.B.1
  • 15
    • 0032892709 scopus 로고    scopus 로고
    • Molecular pathogenesis of secondary hyperparathyroidism in renal failure: Basic and clinical aspects
    • Fukagawa M, Iwasaki Y. Molecular pathogenesis of secondary hyperparathyroidism in renal failure: basic and clinical aspects. Nephrol Dial Transplant 1999;14(suppl):S61-2.
    • (1999) Nephrol Dial Transplant , vol.14 , Issue.SUPPL.
    • Fukagawa, M.1    Iwasaki, Y.2
  • 18
    • 0032920355 scopus 로고    scopus 로고
    • Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis
    • Goldenberg MM. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis. Clin Ther 1999;21:432-41.
    • (1999) Clin Ther , vol.21 , pp. 432-441
    • Goldenberg, M.M.1
  • 19
    • 0032954950 scopus 로고    scopus 로고
    • Effects of new analogues of vitamin D on bone cells: Implications for treatment of uremic bone disease
    • McIntyre CW, Schroeder NJ, Burrin JM, Cunningham J. Effects of new analogues of vitamin D on bone cells: implications for treatment of uremic bone disease. Kidney Int 1999;55:500-11.
    • (1999) Kidney Int , vol.55 , pp. 500-511
    • McIntyre, C.W.1    Schroeder, N.J.2    Burrin, J.M.3    Cunningham, J.4
  • 21
    • 14644392186 scopus 로고    scopus 로고
    • Are new vitamin D analogues in renal bone disease superior to calcitriol?
    • DOI 10.1007/s00467-004-1778-2
    • Salusky IB. Are new vitamin D analogues in renal bone disease superior to calcitriol? Pediatr Nephrol 2005;20:393-8. DOI 10.1007/s00467-004-1778-2
    • (2005) Pediatr Nephrol , vol.20 , pp. 393-398
    • Salusky, I.B.1
  • 22
    • 0033257480 scopus 로고    scopus 로고
    • Doxercalciferol
    • Doxercalciferol. Am J Health Syst Pharm 1999;56:2410-1.
    • (1999) Am J Health Syst Pharm , vol.56 , pp. 2410-2411
  • 23
    • 33750999268 scopus 로고    scopus 로고
    • (New Drug Application no. 20-862/S-018). Madison, WI: Bone Care International, reviewed June
    • Product information. Hectorol (doxercalciferol) (New Drug Application no. 20-862/S-018). Madison, WI: Bone Care International, reviewed June 2005.
    • (2005) Product Information. Hectorol (Doxercalciferol)
  • 24
    • 0031769002 scopus 로고    scopus 로고
    • Vitamin D analogues
    • Brown AJ. Vitamin D analogues. Am J of Kidney Dis 1998;32(suppl 2):S25-39.
    • (1998) Am J of Kidney Dis , vol.32 , Issue.SUPPL. 2
    • Brown, A.J.1
  • 25
    • 0036411910 scopus 로고    scopus 로고
    • Vitamin D analogues for secondary hyperparathyroidism
    • Brown AJ, Dusso AS, Slatopolsky E. Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transplant 2002;17(suppl 10):10-9.
    • (2002) Nephrol Dial Transplant , vol.17 , Issue.SUPPL. 10 , pp. 10-19
    • Brown, A.J.1    Dusso, A.S.2    Slatopolsky, E.3
  • 27
    • 0037384889 scopus 로고    scopus 로고
    • Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone
    • Upton RA, Knutson JC, Bishop CW, LeVan LW. Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone. Nephrol Dial Transplant 2003;18:750-8.
    • (2003) Nephrol Dial Transplant , vol.18 , pp. 750-758
    • Upton, R.A.1    Knutson, J.C.2    Bishop, C.W.3    Levan, L.W.4
  • 28
    • 33750999268 scopus 로고    scopus 로고
    • (New Drug Application no. 21-027/S-012). Madison, WI: Bone Care International, reviewed June
    • Product information. Hectorol injection (doxercalciferol) (New Drug Application no. 21-027/S-012). Madison, WI: Bone Care International, reviewed June 2005.
    • (2005) Product Information. Hectorol Injection (Doxercalciferol)
  • 29
    • 8044230723 scopus 로고    scopus 로고
    • 2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism
    • 2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 1997;51:317-23.
    • (1997) Kidney Int , vol.51 , pp. 317-323
    • Tan Jr., A.U.1    Levine, B.S.2    Mazess, R.B.3
  • 30
    • 17144459471 scopus 로고    scopus 로고
    • 2) in dialysis patients with secondary hyperparathyroidism: A sequential comparison
    • DOI 10.1053/ajkd.2001.22077
    • 2) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 2001;37:532-43. DOI 10.1053/ajkd.2001. 22077
    • (2001) Am J Kidney Dis , vol.37 , pp. 532-543
    • Maung, H.M.1    Elangovan, L.2    Frazao, J.M.3
  • 31
    • 1942466552 scopus 로고    scopus 로고
    • Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4
    • Coburn JW, Maung HM, Elangovan L, et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 2004;43:877-90.
    • (2004) Am J Kidney Dis , vol.43 , pp. 877-890
    • Coburn, J.W.1    Maung, H.M.2    Elangovan, L.3
  • 32
    • 0033624518 scopus 로고    scopus 로고
    • 2) therapy for secondary hyperparathyroidism
    • DOI 10.1053/ajkd2000.16193
    • 2) therapy for secondary hyperparathyroidism. Am J Kidney Dis 2000;30:550-61. DOI 10.1053/ajkd2000.16193
    • (2000) Am J Kidney Dis , vol.30 , pp. 550-561
    • Frazao, J.M.1    Elangovan, L.2    Maung, H.M.3
  • 33
    • 0031637872 scopus 로고    scopus 로고
    • 2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients
    • 2 Study Group
    • 2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. Nephrol Dial Trans 1998;13(suppl3):S68-72.
    • (1998) Nephrol Dial Trans , vol.13 , Issue.SUPPL. 3
    • Frazao, J.M.1    Chesney, R.W.2    Coburn, J.W.3
  • 34
    • 0026785324 scopus 로고
    • Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients
    • Gallieni M, Brancaccio D, Padovese P, et al. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Kidney Int 1992;42:1191-8.
    • (1992) Kidney Int , vol.42 , pp. 1191-1198
    • Gallieni, M.1    Brancaccio, D.2    Padovese, P.3
  • 35
    • 0034049012 scopus 로고    scopus 로고
    • Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients
    • Indridason OS, Quarles D. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Kidney Int 2000;57:282-92.
    • (2000) Kidney Int , vol.57 , pp. 282-292
    • Indridason, O.S.1    Quarles, D.2
  • 37
    • 0037378444 scopus 로고    scopus 로고
    • Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism
    • Sprague SM, Llach F, Amdahl M, Taccetta C, Battle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003;63:1483-90.
    • (2003) Kidney Int , vol.63 , pp. 1483-1490
    • Sprague, S.M.1    Llach, F.2    Amdahl, M.3    Taccetta, C.4    Battle, D.5
  • 38
    • 29144522280 scopus 로고    scopus 로고
    • Inhibition of parathyroid hormone: A dose equivalency study of paricalcitol and doxercalciferol
    • DOI 10.1159/000089707
    • Zisman AL, Ghantous W, Schinleber P, Roberts L. Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol. Am J Nephrol 2005;25:591-5. DOI 10.1159/000089707
    • (2005) Am J Nephrol , vol.25 , pp. 591-595
    • Zisman, A.L.1    Ghantous, W.2    Schinleber, P.3    Roberts, L.4
  • 39
    • 0036023018 scopus 로고    scopus 로고
    • Oral doxercalciferol therapy for secondary hyperparathyroidism in a peritoneal dialysis patient
    • Sprague SM, Ho LT. Oral doxercalciferol therapy for secondary hyperparathyroidism in a peritoneal dialysis patient. Clin Nephrol 2002;58:1555-60.
    • (2002) Clin Nephrol , vol.58 , pp. 1555-1560
    • Sprague, S.M.1    Ho, L.T.2
  • 40
    • 0038715733 scopus 로고    scopus 로고
    • 2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy
    • 2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy. Clin Nephrol 2003;59:471-4.
    • (2003) Clin Nephrol , vol.59 , pp. 471-474
    • Parisi, M.S.1    Oliveri, B.2    Somoza, J.3    Mautalen, C.4
  • 45
    • 0037512524 scopus 로고    scopus 로고
    • Use of active vitamin D sterols in patients with chronic kidney disease, stages 3 and 4
    • Coburn JW, Maung HM. Use of active vitamin D sterols in patients with chronic kidney disease, stages 3 and 4. Kidney Int 2003;63(suppl 85): S49-53.
    • (2003) Kidney Int , vol.63 , Issue.SUPPL. 85
    • Coburn, J.W.1    Maung, H.M.2
  • 46
    • 33750968410 scopus 로고    scopus 로고
    • K/DOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease
    • (accessed 2005 Aug 10)
    • K/DOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. National Kidney Foundation DOQI Guidelines. www.kidney.org/professionals/kdoqi/guidelines_bone/index.htm (accessed 2005 Aug 10).
    • National Kidney Foundation DOQI Guidelines
  • 48
    • 0032944582 scopus 로고    scopus 로고
    • A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients
    • Bleyer AJ, Burke SK, Dillon M, et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999;33:694-701.
    • (1999) Am J Kidney Dis , vol.33 , pp. 694-701
    • Bleyer, A.J.1    Burke, S.K.2    Dillon, M.3
  • 49
    • 0036310682 scopus 로고    scopus 로고
    • Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients
    • Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52.
    • (2002) Kidney Int , vol.62 , pp. 245-252
    • Chertow, G.M.1    Burke, S.K.2    Raggi, P.3
  • 50
    • 0038386468 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia
    • Joy MS, Finn W. Randomized, double-blind, placebo-controlled dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003;42:96-107.
    • (2003) Am J Kidney Dis , vol.42 , pp. 96-107
    • Joy, M.S.1    Finn, W.2
  • 51
    • 21044458627 scopus 로고    scopus 로고
    • Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease
    • Chiang SS, Chen JB, Yang WC. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. Clin Nephrol 2005;63:461-70.
    • (2005) Clin Nephrol , vol.63 , pp. 461-470
    • Chiang, S.S.1    Chen, J.B.2    Yang, W.C.3
  • 52
    • 0038187803 scopus 로고    scopus 로고
    • A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients
    • D'Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003;63(suppl 85):S73-8.
    • (2003) Kidney Int , vol.63 , Issue.SUPPL. 85
    • D'Haese, P.C.1    Spasovski, G.B.2    Sikole, A.3
  • 53
    • 20544460709 scopus 로고    scopus 로고
    • Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study
    • DOI 10.1681/ASN2004060512
    • Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005;16;800-7. DOI 10.1681/ASN2004060512
    • (2005) J Am Soc Nephrol , vol.16 , pp. 800-807
    • Lindberg, J.S.1    Culleton, B.2    Wong, G.3
  • 54
    • 11144353767 scopus 로고    scopus 로고
    • Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis
    • Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-25.
    • (2004) N Engl J Med , vol.350 , pp. 1516-1525
    • Block, G.A.1    Martin, K.J.2    De Francisco, A.L.3
  • 55
    • 0042343804 scopus 로고    scopus 로고
    • Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy
    • Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus M, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-56.
    • (2003) N Engl J Med , vol.349 , pp. 446-456
    • Teng, M.1    Wolf, M.2    Lowrie, E.3    Ofsthun, N.4    Lazarus, M.5    Thadhani, R.6
  • 56
    • 20844459261 scopus 로고    scopus 로고
    • Activated injectable vitamin D and hemodialysis survival: A historical cohort study
    • DOI 10-1681/ASN.2004070573
    • Teng M, Wolf M, Ofsthun N, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005;16:1115-25. DOI 10-1681/ASN.2004070573
    • (2005) J Am Soc Nephrol , vol.16 , pp. 1115-1125
    • Teng, M.1    Wolf, M.2    Ofsthun, N.3
  • 57
    • 20844433851 scopus 로고    scopus 로고
    • Which vitamin D derivative to prescribe for renal patients
    • Drueke TB. Which vitamin D derivative to prescribe for renal patients. Curr Opin Nephrol Hyperten 2005;14:343-9.
    • (2005) Curr Opin Nephrol Hyperten , vol.14 , pp. 343-349
    • Drueke, T.B.1
  • 58
    • 20544454243 scopus 로고    scopus 로고
    • Difficulties in achieving the K/DOQI practice guidelines for bone and mineral metabolism
    • Gonzalez EA, Al-Aly Z, Martin KJ. Difficulties in achieving the K/DOQI practice guidelines for bone and mineral metabolism. Semin Dial 2005;18:171-4.
    • (2005) Semin Dial , vol.18 , pp. 171-174
    • Gonzalez, E.A.1    Al-Aly, Z.2    Martin, K.J.3
  • 59
    • 23844456273 scopus 로고    scopus 로고
    • Beyond minerals and parathyroid hormone: Role of active vitamin D in end-stage renal disease
    • Wolf M, Thadhani R. Beyond minerals and parathyroid hormone: role of active vitamin D in end-stage renal disease. Semin Dial 2005;18:302-6.
    • (2005) Semin Dial , vol.18 , pp. 302-306
    • Wolf, M.1    Thadhani, R.2
  • 60
    • 23844437946 scopus 로고    scopus 로고
    • The role of vitamin D in vascular calcification in chronic kidney disease
    • Wolisi G, Moe SM. The role of vitamin D in vascular calcification in chronic kidney disease. Semin Dial 2005;18:307-14.
    • (2005) Semin Dial , vol.18 , pp. 307-314
    • Wolisi, G.1    Moe, S.M.2
  • 61
    • 33751002265 scopus 로고    scopus 로고
    • McKesson Corporation. San Francisco, California, (accessed 2006 May 19)
    • McKesson Corporation. San Francisco, California, http://supply.mckesson. com/portal/site/smoportal (accessed 2006 May 19).


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.